Table 1.

Response evaluation criteria in solid tumours (RECIST) [19], world health organisation (WHO) [19], and european association for study of the Liver (EASL) [20].

	RECIST change in sum of the longest diameters	WHO change in sum of products	EASL
Complete response (CR)	Disappearance of all target lesions at 4 weeks	Disappearance of all target lesions at 4 weeks	100% necrosis of target lesions and no new lesions
Partial response (PR)	30% decrease in the Longest Diameter (LD) of target lesions at 4 weeks	50% decrease confirmed at 4 weeks	50–99% increase in necrosis
Stable disease (SD)	Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD	Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD	<50% increase in necrosis
Progressive disease (PD)	At least a 20% increase in the LD of target lesions; no CR, PR, or SD documented before increase	25% increase; no CR, PR, or SD documented before increase	≥25% increase in ≥1 lesion or ≥1 new lesion

CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.